Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL
Trial shows new treatment improves progression-free survival for lymphoma
This Phase 3 randomized, double-blind, placebo-controlled trial evaluated tafasitamab plus lenalidomide and R-CHOP in patients with high-ris…
A new drug combination showed improved progression-free survival for patients with high-risk large B-cell lymphoma in a Phase 3 clinical tri…
Venetoclax-based combinations show superior progression-free survival compared to chemoimmunotherapy in CLL without TP53 aberrations
Trial shows venetoclax combinations improve progression-free survival in CLL
This Phase 3 randomized controlled trial of 926 patients with CLL without TP53 aberrations found that venetoclax-based regimens (RV, GV, and…
New clinical trial results show that specific venetoclax combinations can keep chronic lymphocytic leukemia stable for longer than standard …
Bendamustine and rituximab treatment for Waldenström macroglobulinemia with renal AL amyloidosis shows hematologic response
New treatment approach shows promise for rare blood cancer
This case report describes a 71-year-old woman with Waldenström macroglobulinemia and renal AL amyloidosis treated with bendamustine plus ri…
A new drug combination helped a patient with a rare blood cancer and kidney issues, but it requires very careful monitoring.
Mechanism-based strategies including CAR-T and bispecific engagers offer options for rituximab-resistant primary membranous nephropathy
New Strategies Target Treatment Resistance in Membranous Nephropathy
This systematic review examines the multifactorial mechanisms of rituximab resistance in patients with primary membranous nephropathy. It id…
Researchers identify new ways to treat primary membranous nephropathy when standard rituximab treatments do not work.
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors
Biologics for arthritis: Cancer risk appears low overall
This narrative review of biologic and targeted synthetic DMARDs in immune-mediated inflammatory arthritides finds most therapies have reassu…
Most biologic arthritis drugs don't raise overall cancer risk, but skin cancer risk may be higher with some.
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
New immunotherapy options offer high response rates for Diffuse Large B-Cell Lymphoma patients
This narrative review surveys immunotherapy options for diffuse large B-cell lymphoma beyond rituximab, including bispecific antibodies, CAR…
New immunotherapy treatments show high response rates for Diffuse Large B-Cell Lymphoma, offering hope beyond the standard 60% success rate …
Rituximab rechallenge caused severe hypersensitivity reaction in a patient with membranous nephropathy
A third Rituximab dose caused severe shock in a man with kidney disease
This case report describes a 52-year-old male with biopsy-proven primary membranous nephropathy who received a third 1 g infusion of rituxim…
A man with kidney disease developed life-threatening shock after a third Rituximab infusion, highlighting the need for careful monitoring an…
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
Case report of obinutuzumab-induced acute bicytopenia in autoimmune disease
A Common Lupus Drug Caused a Man's Platelets to Nearly Disappear
This is a case report and literature review describing a 55-year-old male with ANCA-associated glomerulonephritis who developed acute thromb…
A man with autoimmune kidney disease lost nearly all his platelets after a common cancer drug, and doctors say the warning signs were hiding…